News
Trabectedin bests supportive care in advanced soft-tissue sarcomas
CHICAGO – The benefit of trabectedin vs. best supportive care was entirely in patients with leiomyosarcoma or liposarcoma.
News
Rare clear cell papillary RCC has indolent course
This tumor type, first recognized as a distinct entity in 2016, is associated with low risk of recurrence or distant metastasis.
News
Insurance is a matter of life or death for lymphoma patients
Improving patient access to affordable private insurance could improve survival outcomes for patients with follicular lymphoma.
News
Conditional OS estimates show upfront TKI benefit in mRCC
Patients who survived at least 36 months after starting on a TKI had an estimated 36-month conditional OS rate 7.3% higher than had been predicted...
News
HPV positivity associated with good esophageal adenocarcinoma outcomes
Patients with esophageal adenocarcinoma who were HPV positive had significantly better disease-free and overall survival.
News
Melanoma diagnosis does not deter pregnancy
Women with melanoma who became pregnant were not at increased risk for recurrence, a review of a claims database suggests.
News
Intrathecal methotrexate dosing in acute leukemia falls short
STOCKHOLM – Scheduling and staffing changes could help improve the efficacy of CNS chemoprophylaxis in acute lymphoblastic leukemia.
News
Gene assays reveal some ‘unknown primary’ cancers as RCC
RCC-specific therapy in this small patient sample was associated with better survival than was empiric chemotherapy.
News
Rituximab reduces risk of follicular lymphoma transformation
Rituximab-based chemotherapy and maintenance was associated with significantly lower risk of FL transformation from indolent to aggressive.
News
Symptom clusters may identify cancer patients at risk for hospitalization
Combing through electronic health records could help clinicians spot patients at risk for potentially preventable acute hospitalizations.
News
PARP inhibitors didn’t impair QOL as ovarian cancer maintenance therapy
Despite significant hematologic toxicities, PARP inhibitors did not adversely affect health-related quality of life for ovarian cancer patients....
News
Adding elotuzumab improves myeloma PFS over pom/dex alone
STOCKHOLM – Elotuzumab, pomalidomide, and dexamethasone improved progression-free survival and responses, compared with pom/dex alone in patients...
News
No survival boost with atezolizumab vs. regorafenib in mCRC
BARCELONA – There was no overall or progression-free survival benefit from the PD-L1 inhibitor with or without cobimetinib vs. regorafenib alone...
News
IVF linked to slight increase in risk of some cancers
A large observational study found no increase in risk for uterine cancer, but small increases in risk of some breast and ovarian cancers in women...
News
Ibrutinib/venetoclax shows early promise in relapsed CLL
STOCKHOLM – An ongoing study shows a high clinical response rate and acceptable safety profile with the chemotherapy-free targeted therapy...